A7986

Atovaquon

≥98% (HPLC), powder, anti-protozoal agent

• Synonym(e): 2-[trans-4-(4-Chlorphenyl)cyclohexyl]-3-hydroxy-1,4-naphthochinon, Mepron
• Empirische Formel (Hill-System): C₂₂H₁₉ClO₃
• CAS-Nummer: 95233-18-4
• Molekulargewicht: 366.84
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329770944
• NACRES: NA.77

Eigenschaften

• product name: Atovaquon, ≥98% (HPLC)
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: yellow
• Löslichkeit: DMSO: >10 mg/mL
• Ersteller: GlaxoSmithKline
• Lagertemp.: −20°C
• SMILES String: OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O
• InChI: 1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-
• InChIKey: KUCQYCKVKVOKAY-CTYIDZIISA-N

Beschreibung

Anwendung

Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.

Biochem./physiol. Wirkung

Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.

Leistungsmerkmale und Vorteile

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable